SLC5A2 and heart failure: Outcomes of empagliflozin across the diabetic and cardiovascular spectrum: Studies consistently show that SGLT2 inhibitors, as opposed to other antihyperglycemic medications, reduce the likelihood of heart failure hospitalizations and serious renal outcomes in diabetic patients [18-20].